MET and non-small cell lung carcinoma: Olafertinib (CK-101/RX518) (59) is an oral selective EGFR covalent inhibitor approved for second-line treatment in patients with EGFRT790M mutation NSCLC and first-line treatment in patients with EGFR sensitive mutation (Del19, L858R) NSCLC.172 The drug also shows promise in combination therapy with immune checkpoint inhibitors (PD-1 or PD-L1), c-Met inhibitors, and Mek inhibitors, as demonstrated by preclinical studies.